Amgen

Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.

Researchers identified truncating, psychosis-related mutations in RBM12 in a family affected by schizophrenia or other psychosis disorders.

Using extensive genetic data from an Icelandic population, researchers identified two rare variants associated with osteoarthritis and related hip replacements.

Lower, But…

A trial of a drug that mimics a PCSK9 gene mutation doesn't quite meet expectations, both Nature News and Forbes say.

This Week in PLOS

In PLOS this week: mitochondrial mutation linked to tubulointerstitial kidney disease, asthma protection variant, and more.

The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL. 

The company plans to use the funds to build up a Dublin-based genomic research and development program based on the model of Iceland's Decode Genetics.

The deal follows a June agreement under which Exosome is developing an exosomal RNA sequencing platform with Takeda.

A study in NEJM found that rare, loss-of-function mutations in the asialoglycoprotein receptor gene coincide with lower non-HDL levels and decreased coronary artery disease risk.

DeCode Genetics' Kari Stefansson and his colleagues uncovered a dozen genetic variants that influence blood lipids, and explored links to coronary artery disease.

Pages

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.